linjc16/ctgov huggingface dataset:
Fast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint Inhibitors

Study Overview
=================
Brief Summary
-----------------
Prospective study cohort on patients addressed for suspected cardiovascular event on immune checkpoint inchibitors. Longitudinal prospective single center cohort. Inclusion criteria: all patient willing to particiupate seen in the cardio-oncology unit at our institution for the suspicion of heart failure, atherosclerosis related event, Tako Tsubo, arrhymias, pericarditis, myocarditis on antiPD1, antiPDL1, or antiCTLA4 immune checkpoint inhibitors. Description of patients characteristics, investigations, diagnosis after multidisciplinary meeting, outcomes.

Official Title
-----------------
Fast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint Inhibitors: Prospective Cohort Study.

Conditions
-----------------
Cancer, Immune Checkpoint Inhibitor, Cardiovascular Complication, Immune-related Adverse Event

Intervention / Treatment
-----------------
* Other: No intervention for research purposes only


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patient referred to the cardio oncology unit for suspected immune related cardiovascular complication on immune checkpoint inhibitors Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No intervention for research purposes only|No intervention for research purposes only|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Major cardiovascular event | Composite endpoint: acute coronary syndrome, myocarditis, pericarditis, heart failure, Taki Tsubo, ventricvular arrhymias | 12 months |
VTE Incidence After Curative Colon Cancer Surgery in an ERAS Program

Study Overview
=================
Brief Summary
-----------------
Based on data on a cohort of 2,141 patients undergoing elective colonic cancer resection in an ERAS program, the incidence of postoperative thromboembolic events is estimated in patients no receiving prolonged thromboembolic prophylaxis.

Detailed Description
-----------------
The Copenhagen cOmplete Mesocolic Excision Study (COMES) database contains comprehensive data on preoperative, intraoperative, postoperative and tumor related variable on patients undergoing elective colonic cancer resection at four public university clinics providing all colorectal cancer treatment for the 1.8 million residents of the Capital Region of Denmark during the period 2014-2017. None of these hospitals had implemented prolonged thromboembolic prophylaxis after discharge. The medical records were reviewed with focusing on VTE prophylaxis, ongoing preoperative and postoperative anticoagulant treatment, the length of hospital stay (LOS), and readmission to ensure high data validity.

Official Title
-----------------
Incidence of Venous Thrombotic Event After Curative Colon Cancer Surgery in an Enhanced Recovery After Surgery Program

Conditions
-----------------
Deep Vein Thrombosis, Pulmonary Embolus, Colon Cancer

Intervention / Treatment
-----------------
* Procedure: Colon resection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: elective macroradical resection for UICC Stage I-III colonic adenocarcinoma Exclusion Criteria: concomitant rectum resection soly appendix carcinoma diagnosed with pulmonary embolism or deep venous thrombosis before primary discharge dying before discharge from the hospital or discharged at postoperative day 28 or later treatment with vitamin K antagonists, heparin or new oral anticoagulants before or after surgery VTE less than 3 months before the colon resection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Colon resection|Colon cancer resection|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative venous thromboembolic event | Deep venous thrombosis or pulmonary embolism | 60 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prolonged thromboembolic prophylaxis
M-TACE Treatment for Unresectable Hepatocellular Carcinoma

Study Overview
=================
Brief Summary
-----------------
This study aims to investigate the safety and efficacy of transarterial chenmoembolization（TACE） combined with microspheres for unresectable hepatocellular carcinoma(HCC).

Official Title
-----------------
Lipiodol Combined With Microspheres TACE for Unresectable HCC

Conditions
-----------------
Hepatocellular Carcinoma

Intervention / Treatment
-----------------
* Procedure: M-TACE


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18≤Age<80 on day of signing informed consent. Have histologically confirmed diagnosis or radiological diagnosis of HCC with at least one >3cm targeted lesion. Have Barcelona Clinic Liver Cancer (BCLC) Stage C disease or BCLC Stage B disease, BCLC stage A disease but refuse a surgical or ablation therapy. Have a Child-Pugh Class A/B（<7） liver score. Have a performance status of 0 or 1 using the ECOG. Have a predicted life expectancy of greater than 3 months. Exclusion Criteria: The targeted lesions have received TACE or other locoregional therapy within 3 months. Tumor burden over 70% of the liver volume. Lesions can not be measured by mRECIST. Has a diagnosed additional malignancy. Patients with Hb<9.0g/dL, WBC<1.0×10^9/L， TB>3mg/dL，ALT/AST>5 UL, ALB<2.8g/dL， INR>2.3, Cr >2mg/mL or CCr<30mL/min. Severe heart, lung or cerebral disease.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: M-TACE<br> | Procedure: M-TACE<br>* Lipiodol combined with microspheres<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ORR | Objective response rate according to the mRECIST | 1 month after first mTACE | 
| ORR | Objective response rate according to the mRECIST | 3 months after first mTACE | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| OS | Overall survival | 1 year | 
| OS | Overall survival | 3 years |
Aortic Stenosis With COmplex PCI (ASCOP) Features Retrospective Registry on Contemporary Management and Outcomes

Study Overview
=================
Brief Summary
-----------------
To describe the prevalence and clinical features of patients with severe aortic stenosis undergoing TAVI and concomitant clinically indicated, complex and/or high-risk PCI

Detailed Description
-----------------
The aims of this study are: to describe the prevalence and clinical features of patients with severe aortic stenosis undergoing TAVI and concomitant clinically indicated, complex and/or high-risk PCI to depict the different possible strategies that are currently employed in this context and to retrospectively analyze outcomes to investigate predictors of better outcomes

Official Title
-----------------
Aortic Stenosis With COmplex PCI (ASCOP) Features Retrospective Registry on Contemporary Management and Outcomes

Conditions
-----------------
Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement, Angioplasty, Balloon, Coronary, Coronary Artery Disease

Intervention / Treatment
-----------------
* Procedure: Transcatheter aortic valve intervention (TAVI) and percutaneous coronary intervention (PCI)


Participation Criteria
=================
Eligibility Criteria
-----------------
Severe, symptomatic aortic stenosis with an indication to TAVI Concomitant, stable CAD with an indication to complex PCI, as anticipated by angiography, defined as follows (one or more features) Left-main (LM) CAD or proximal left anterior descending (LAD) / left circumflex (LCx) lesions requiring LM-PCI Three-vessel disease Last remaining vessel Bifurcation PCI (proximal bifurcation) Severely calcified lesions requiring calcium plaque modification (rotational/orbital atherectomy, intravascular lithotripsy, scoring or cutting balloon) Lesion length > 30 mm Severely depressed Left ventricular function requiring mechanical circulatory support (intra-aortic balloon pump - IABP, Impella, Extracorporeal Membrane Oxygenation - ECMO

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ASCoP (severe Aortic Stenosis with Complex PCI features)<br>Subjects with severe aortic stenosis undergoing transcatheter aortic valve intervention and with concomitant, complex coronary artery disease with a clinical indication for percutaneous coronary intervention | Procedure: Transcatheter aortic valve intervention (TAVI) and percutaneous coronary intervention (PCI)<br>* TAVI and PCI to be administered as per physician's indication and choice, in one or more stages<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| POCE | all-cause deaths, strokes (any), myocardial infarction and major bleedings | 1 year |
A Real-World Study of COVID-19 Infection in Patients With Malignant Lymphomas Participating in Clinical Trials

Study Overview
=================
Brief Summary
-----------------
This study focuses on the population of malignant lymphoma patients who are also in clinical research. Through a real world cross-sectional survey of infection and death risk during the COVID-19 pandemic in Guangzhou from December 2022 to January 2023, this study aims to clarify the risk, level and mortality of lymphoma patients infected with COVID-19 during their clinical research, and provide necessary research data for Chinese lymphoma patients during the COVID-19 pandemic,

Official Title
-----------------
A Real-World Study of COVID-19 Infection in Patients With Malignant Lymphomas Participating in Clinical Trials

Conditions
-----------------
Malignant Lymphoma, Clinical Trial, COVID-19

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: (1) the diagnosis of lymphoma was confirmed by pathology according to World Health Organization (WHO)-criteria; (2) diagnosed with COVID-19 based on a positive polymerase chain reaction (PCR) test result for SARS-CoV-2 from oropharyngeal swabs, or on a positive detection of covid-19 antigen from nasopharyngeal swabs and typical clinical history; (3) participated in registered clinical trials and received anti-lymphoma treatment within four weeks before COVID-19 infection; (4) complete data on clinico-pathological characteristics, treatment approaches and follow-up were available. Exclusion Criteria: Patients who could not provide detailed information about COVID-19 infection.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No intervention|No intervention needed|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The severity of COVID-19 | The severity of COVID-19 infection in maligant lymphoma patients evaluated by investigators | 2 months | 
| Hospital admission rate of COVID-19 infection | The percentage of malignant lymphoma patients who were admitted into hospital | 2 months |
Comparison of Lumbar Muscle Thickness Measurements in Osteoporotic and Osteopenic Patients

Study Overview
=================
Brief Summary
-----------------
In osteoporosis, sarcopenia is a common condition. Sarcopenic measurements can be made by evaluating muscle thickness in different regions. We aim to evaluate lumbar muscle losses in patients with osteoporosis in the lumbar region and to examine whether these muscle losses are correlated with the level of osteoporosis. The patients will be divided into 3 groups as healthy, osteopenic and osteoporotic according to DEXA measurements. Demographic values, comorbidities, osteoporosis drugs used, fracture histories, L1-4, L2-4, femoral neck and total BMD and t values of the patients, psoas and multifidus muscle measurements will be made at L2-L3 level in Lumbar MR imaging. Lumbar MR muscle measurements will be made by 1 physician blind to the DEXA values of the patients.

Official Title
-----------------
Comparison of Lumbar Muscle Thickness Measurements in Osteoporotic and Osteopenic Patients

Conditions
-----------------
Osteoporosis

Intervention / Treatment
-----------------
* Diagnostic Test: Lomber Muscle Thickness Measurement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 50-90 years old 2. Recent MRI of the lumbar region with DEXA evaluation Exclusion Criteria: Have had previous lumbar surgery Any previous lumbar injection Stage 3-4 Lumbar Listesis Presence of Lumbar Discopathy accompanied by neurological deficit

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Ostoporotic Patients Group<br>T value of -2.5 and below in DEXA measurement | Diagnostic Test: Lomber Muscle Thickness Measurement<br>* Muscle thickness measurements will be made on the imaging of those who have lumbar MR imaging.<br>|
| Osteopenic Patients Group<br>T value between -2.5 and -1 in DEXA measurement | Diagnostic Test: Lomber Muscle Thickness Measurement<br>* Muscle thickness measurements will be made on the imaging of those who have lumbar MR imaging.<br>|
| Healthy Group<br>T value of -1 and above in DEXA measurement | Diagnostic Test: Lomber Muscle Thickness Measurement<br>* Muscle thickness measurements will be made on the imaging of those who have lumbar MR imaging.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lomber Muscle Measurement | Psoas and multifidus muscle measurements will be made at L2-L3 level in Lumbar MR imaging. | Day 1 |
Influence of Implant Crown Transmucosal Contour Design on Soft and Hard Tissue Clinical Outcomes

Study Overview
=================
Brief Summary
-----------------
This study will evaluate how the crown's shape under the gums will influence the gum tissue around dental implants.

Detailed Description
-----------------
This research is studying the transmucosal contour, or shape of crowns (white-colored tooth structure that sits above the gum) under the gums on dental implants. Participants will be randomly selected for the dental implant crown to be designed with either a straight or concave transmucosal contour, and followed up on for 1 year after crown delivery.

Official Title
-----------------
Influence of Implant Crown Transmucosal Contour Design on Soft and Hard Tissue Clinical Outcomes

Conditions
-----------------
Gum Disease

Intervention / Treatment
-----------------
* Procedure: Implant crown delivery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria Be a current participant of HUM00208140 main study Have a dental implant that is ready to be restored (placed at least 3 months ago and healing is adequate) Exclusion Criteria: • The dental implant crown was already delivered.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Straight transmucosal contour<br>Implant crown will be designed with a straight transmucosal contour | Procedure: Implant crown delivery<br>* Dental implant crown will be designed, fabricated by a dental lab, and delivered.<br>|
| Active Comparator: Concave transmucosal contour<br>Implant crown will be designed with a concave transmucosal contour | Procedure: Implant crown delivery<br>* Dental implant crown will be designed, fabricated by a dental lab, and delivered.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Marginal bone loss around dental implant | Measured from radiographs in mm | 6 months and 12 months after crown delivery | 
| Gum tissue thickness | Measured from intraoral scan in mm | 6 months and 12 months after crown delivery | 
| Gingival margin height | Measured from intraoral scan in mm | 6 months and 12 months after crown delivery | 
| Amount of keratinized gingiva | Measured clinically in mm | 6 months and 12 months after crown delivery |
Comparison Of Effectiveness of Mobilization With Movement (MWM) and Kelternborn Treatment Technique to Increase ROM, Reducing Pain in Patient of ACL Reconstruction

Study Overview
=================
Brief Summary
-----------------
To determine the Comparison Of Effectiveness of Mobilization With Movement (MWM) and Kelternborn Treatment Technique to Increase ROM, Reducing Pain in Patient of ACL Reconstruction

Official Title
-----------------
Comparison Of Effectiveness of Mobilization With Movement (MWM) and Kelternborn Treatment Technique to Increase ROM, Reducing Pain in Patient of ACL Reconstruction

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Diagnostic Test: Mobilization With Movement (MWM)
* Diagnostic Test: Kelternborn Treatment Technique


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • Subjects with age group between 20 to 60 years with sedentary lifestyle were included. Both males and females were included. Patients with diagnosed Tight hamstrings having knee extension less than 160º with the hip at 90º flexion. Patients with decreased ROM at the knee joint. Patients with reduced straight leg raise. Patients with pain in posterior compartment of thigh. Asymptomatic patients will be included. Exclusion Criteria: • Patients with prolapsed disc were excluded. Patients with lower extremity injuries (strain, sprain, ligament injuries, etc.) in last 6 months were excluded. Patients with severe hamstring injury either acute or chronic were excluded. Patients with visual acute swelling in the region of hamstring muscle Patients with fracture of any type and area. Patients with dislocations or subluxations present were excluded. Patient recommended for TKR of knee joint. Patients with any neurological disease like lumbar/cervical herniation, polyneuropathy, scoliosis etc.)

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Mobilization With Movement (MWM)<br> | Diagnostic Test: Mobilization With Movement (MWM)<br>* Mobilization With Movement<br>|
| Experimental: Kelternborn Treatment Technique<br> | Diagnostic Test: Kelternborn Treatment Technique<br>* Kelternborn Treatment Technique<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Goniometer (Range of Motion) |  | 6 Months | 
| Visual Analog Scale ( VAS) |  | 6 Months |
Levator Muscle Reaction for Unilateral Congenital Ptosis Repair as Compared to Levator Plication

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to compare the outcome of levator muscle resection with plication in mild to moderate congenital unilateral blepharoptosis.

Detailed Description
-----------------
Blepharotosis is one of the most encountered oculoplastic problems. Blepharoptosis is an abnormal low lying upper eyelid margin more than 2mm below the superior corneal limbus in the primary gaze position. It can be subdivided according to the amount of levator function into poor (0-5),fair (6-11) or good (12 or more) millimeter. It can be classified also according to the degree of ptosis into mild (2mm) moderate (3mm) and severe ( 4mm or more). Surgical options for each of these groups are based on levator function as well as the degree and the cause of ptosis.

Official Title
-----------------
Levator Muscle Resection for Unilateral Congenital Ptosis Repair as Compared to Levator Plication

Conditions
-----------------
Congenital Ptosis

Intervention / Treatment
-----------------
* Procedure: levator muscle resection
* Procedure: levator muscle plication


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: mild to moderate simple unilateral congenital ptosis with good to fair levator function Exclusion Criteria: severe ptosis poor levator function poor Bell's phenomenon lagophthalmos diminished corneal sensation completed congenital or acquired ptosis history of previous lid surgery
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>evaluation of levator muscle resection on congenital ptosis | Procedure: levator muscle resection<br>* resection of levator muscle in congenital unilateral ptosis<br>|
| Active Comparator: 2<br>evaluation of levator muscle plication on congenital ptosis | Procedure: levator muscle plication<br>* plication of levator muscle in congenital unilateral ptosis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of outcome of levator muscle resection and plication in mild to moderate congenital ptosis | Comparison of surgical efficacy of levator muscle resection and plication regarding lid height as measured by MRD 1 | 6 months |